Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries OKYO Pharma Limited - Ordinary Shares (NQ: OKYO ) 0.9381 -0.0569 (-5.72%) Streaming Delayed Price Updated: 3:59 PM EDT, Aug 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 94,850 Open 1.100 Bid (Size) 0.9200 (6) Ask (Size) 1.060 (1) Prev. Close 0.9950 Today's Range 0.8800 - 1.148 52wk Range 0.8800 - 3.070 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session July 11, 2024 Via Benzinga OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101 July 11, 2024 From OKYO Pharma LTD Via GlobeNewswire Performance YTD -51.64% -51.64% 1 Month -21.82% -21.82% 3 Month -37.04% -37.04% 6 Month -28.93% -28.93% 1 Year -40.25% -40.25% More News Read More OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease July 10, 2024 From OKYO Pharma LTD Via GlobeNewswire OKYO Pharma Announces Participation in May 2024 Investor Conferences May 08, 2024 From OKYO Pharma LTD Via GlobeNewswire OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO) April 30, 2024 From OKYO Pharma LTD Via GlobeNewswire OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024 April 08, 2024 From OKYO Pharma LTD Via GlobeNewswire OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery April 02, 2024 From OKYO Pharma LTD Via GlobeNewswire Why Salarius Pharmaceuticals Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving Premarket March 25, 2024 Via Benzinga Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session March 25, 2024 Via Benzinga Relief For Dry Eye Disease? OKYO Pharma's Candidate Shows Durable Pain Relief In Mid-Stage Study March 22, 2024 Via Benzinga OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101 March 22, 2024 From OKYO Pharma LTD Via GlobeNewswire OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial March 21, 2024 From OKYO Pharma LTD Via GlobeNewswire OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event March 20, 2024 From OKYO Pharma LTD Via GlobeNewswire 12 Health Care Stocks Moving In Friday's After-Market Session March 01, 2024 Via Benzinga 12 Health Care Stocks Moving In Monday's Pre-Market Session February 12, 2024 Via Benzinga 12 Health Care Stocks Moving In Friday's Intraday Session February 09, 2024 Via Benzinga 12 Health Care Stocks Moving In Friday's Pre-Market Session February 09, 2024 Via Benzinga OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain February 09, 2024 From OKYO Pharma LTD Via GlobeNewswire OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board January 31, 2024 From OKYO Pharma LTD Via GlobeNewswire 12 Health Care Stocks Moving In Monday's After-Market Session January 08, 2024 Via Benzinga OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease January 08, 2024 From OKYO Pharma LTD Via GlobeNewswire OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024 January 05, 2024 From OKYO Pharma LTD Via GlobeNewswire OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit December 04, 2023 From OKYO Pharma LTD Via GlobeNewswire OKYO Pharma Announces $5.84 Million Cash Raise and Payables Reduction October 31, 2023 From OKYO Pharma LTD Via GlobeNewswire Dow Rebounds, Still Below Fair Value October 09, 2023 Via Talk Markets Topics Stocks Exposures US Equities Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
